News - Medical and health professional investment - VC and PE investment business - Shenzhen Efung Investment Management Co. Ltd.

发布时间: 2026 - 03 - 30

China's First and World's First Recombinant Type A Botulinum Toxin Approved for Market

On March 25, the National Medical Products Administration (NMPA) officially announced that the Recombinant Type A Botulinum Toxin for Injection (National Drug Approval No. S20260019), developed by Chongqing Yuyan Pharmaceutical Co., Ltd. (a subsidiary of MingMed), has been approved for market. This is China's first and the world's first recombinant technology-produced Type A botulinum toxin, marking a core technological breakthrough in the botulinum toxin field for China and breaking the long-standing monopoly of imported products.Unlike traditional botulinum toxin fermentation process...

浏览次数：3

查看详情>>

发布时间: 2026 - 03 - 25

Frontier Biotechnologies Enters Exclusive License Agreement with GSK for siRNA Pipeline Products

Frontier Biotechnologies Inc. (“Frontier Biotechnologies” or the “Company”) recently entered into an exclusive licensing agreement with global biopharmaceutical company GlaxoSmithKline (“GSK”). Under the agreement, GSK will obtain exclusive worldwide rights for the development, manufacturing, and commercialization of two siRNA pipeline assets. One candidate drug has reached the Investigational New Drug (IND) application stage, while the other is a preclinical candidate.This agreement highlights the Company’s expertise in early-stage siRNA drug discovery and development, marking a significant m...

浏览次数：2

查看详情>>

发布时间: 2026 - 03 - 06

Oryzogen's Orumin® Phase IV Clinical Trial Completes First Dosing | Portfolio News

Oryzogen's Orumin® Phase IV Clinical Trial Completes First Dosing | Portfolio NewsOn March 5, 2026, the Phase IV clinical study of Oryzogen's recombinant human albumin (rice-derived) Orumin®, evaluating its "safety and efficacy in patients with hypoalbuminemia and/or hypovolemia requiring emergency treatment," achieved its first patient enrollment and completed the initial dosing, marking the commencement of the Phase IV clinical stage.Efung Capital first invested in Oryzogen in 2016 and has continued to increase its commitment, participating in two consecutive fina...

浏览次数：3

查看详情>>

发布时间: 2026 - 03 - 05

Viestar’s Confocal Microscopy Products Selected as Outstanding Domestic Medical Equipment

The year 2026 marks the beginning of the 15th Five-Year Plan period. Recently, the 11th batch of the “Outstanding Domestic Medical Equipment Product Catalogue” was officially released. Viestar’s independently developed BIOPSEE® Confocal Laser Endomicroscope and BIOPSEE® Ultra-Thin Probe-based Confocal Laser Endomicroscope were prominently selected. This recognition makes JWS Medical the exclusive selected product in the confocal microscopy field for this batch, securing a “strong start” for the 15th Five-Year Plan with national-level authoritative certification. This achievement lays...

浏览次数：4

查看详情>>